Relinde Lieverse

About

My main PhD project: the international (6 countries) multi-center (15 centra) ImmunoSABR phase 2 trial. (http://www.immunosabr.org) IMMUNOSABR is geared towards opening up a new paradigm in treating metastatic cancer by obtaining clinical proof of concept for a novel bi- and tri-modal curative treatment strategy. High precision stereotactic ablative radiotherapy (SABR) is combined with immunotherapy to form a powerful synergistic anti-tumour strategy. The approach relies on the direct cytotoxic effect of SABR, the abscopal effect of radiation observed at distance from the irradiated metastatic site(s), and the effect of the tumour-specific immunocytokine L19-IL2 and in some cases combined with well-known pembrolizumab.

Experience

• AIOS internal Medicine at UMC Utrecht
  Jun 2025 - Present · 1 yr 2 mos

• JNIV (3 yrs 7 mos)
  • Board Member JNIV
    Jan 2024 - Present · 2 yrs 7 mos

  • Visiteren van de opleiding interne geneeskunde
    Jan 2023 - Present · 3 yrs 7 mos

• Oncology-focused pre-clinical & clinical PhD student at Maastricht UMC+
  Jan 2018 - Present · 8 yrs 7 mos

• AIOS Internal Medicine at Catharina Hospital Eindhoven
  Jan 2021 - Jun 2025 · 4 yrs 6 mos

• EMA - EV Human MAH Trusted Deputy at Maastricht University
  Apr 2020 - Dec 2023 · 3 yrs 9 mos

  Main responsible for Pharmacovigilance - managing and reporting ICSR clinical trial(s) for Maastricht University